

15

Name of Journal: *World Journal of Gastrointestinal Oncology***Manuscript NO:** 52557**Manuscript Type:** ORIGINAL ARTICLE**Retrospective Study****Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib**

Vincenzo Ricci, Cristina Granetto, Antonella Falletta, Matteo Paccagnella, Andrea Abbona, Elena Fea, Teresa Fabozzi, Cristiana Lo Nigro, Marco Carlo Merlano

Abstract**BACKGROUND**

Regorafenib is an oral small-molecule multikinase inhibitor approved in third or later line of treatment for patients with metastatic colorectal cancer (mCRC). Regorafenib has shown significant benefits in overall survival and progression free survival in two phase III trials

Match Overview

1	Crossref 59 words Xia Wang. "Tumor necrosis factor and cancer, buddies or foes?", <i>Acta Pharmacologica Sinica</i> , 11/2008	2%
2	Crossref 56 words "Abstract Book of the 21th National Congress of Italian Association of Medical Oncology (AIOM)", <i>Tumori Journal</i> , 2019	2%
3	Internet 34 words crawled on 03-Dec-2014 www.memorialhermann.org	1%
4	Crossref 30 words Maria Røed Skårderud, Anne Polk, Kirsten Kjeldgaard Vistisen, Finn Ole Larsen, Dorte Lisbet Nielsen. "Efficacy and saf	1%
5	Internet 19 words crawled on 26-Nov-2016 f1000.com	1%
6	Crossref 17 words Yoichiro Yoshida, Atsushi Satoh, Teppei Yamada, Naoya Aisu et al. "The Relationship Between Evaluation Methods fo	<1%
7	Crossref 15 words Lillian M. Smyth, Kelsey R. Monson, Komal Jhaveri, Alexander Drilon et al. "A phase 1b dose expansion study of the pa	<1%
8	Internet 15 words crawled on 15-Nov-2017 rest.oxfordjournals.org	<1%

Circulating cytokines and outcome in metastatic colorectal car



ALL

IMAGES

VIDEOS

关闭取词

53,100 Results

Any time ▾

Survival, safety, and prognostic factors for outcome with ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936193>

Jul 07, 2016 · Survival, safety, and **prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory** to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program. Antoine Adenis, Phone: +33320295942, Email: rf.terbmal-o@sineda-a.

Cited by: 23

Author: Antoine Adenis, Christelle de la Fouchard...

Publish Year: 2016

Angiogenesis genotyping and clinical outcome during ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846860>

Regorafenib monotherapy is a potential option for **metastatic colorectal cancer patients**. However, the lack of predictive **factors** and the **severe toxicities** related to **treatment** have made its use in clinical practice challenging.

Cited by: 10

Author: Riccardo Giampieri, Lisa Salvatore, Mich...

Publish Year: 2015

Functional imaging and circulating biomarkers of response ...

<https://gut.bmj.com/content/67/8/1484> ▾

Aug 01, 2018 · **Colorectal cancer (CRC)** remains a major health burden with significant morbidity and mortality despite recent improvements in its management owing to better screening and therapeutic options.¹ CRC is known to be a biologically heterogeneous **disease** characterised by the activation of several angiogenic and oncogenic pathways.² **Regorafenib**, a multikinase inhibitor with known anti-angiogenic, antistromal and anti-oncogenic activities,³ has demonstrated single agent **efficacy in patients with ...**



Circulating cytokines and outcome in metastatic colorectal car



Sign in



ALL

IMAGES

VIDEOS

关闭取词

Add Bing Firefox extension >

52,700 Results

Any time ▾

Survival, safety, and prognostic factors for outcome with ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936193>

Jul 07, 2016 · Survival, safety, and **prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory** to standard therapies: results from a multicenter study (**REBACCA**) nested within a compassionate use program. Antoine Adenis, Phone: +33320295942, Email: rf.terbmal-o@sineda-a.

Cited by: 23

Author: Antoine Adenis, Christelle de la Fouchard...

Publish Year: 2016

Early modifications of circulating microRNAs levels in ...

<https://www.nature.com/articles/s41397-019-0075-3>

Jan 28, 2019 · Biomarkers able to improve the cost/benefit ratio are urgently needed for **metastatic colorectal cancer patients** that are eligible to receive **regorafenib**. Here, we measured **plasma levels** of ten **circulating microRNAs (c-miRNAs)** and we investigated their early changes during **treatment**, as well as possible correlation with **clinical outcome**.

Cited by: 1

Author: Marta Schirripa, Beatrice Borelli, Romina ...

Publish Year: 2019

Author: [Marta Schirripa](#)